Evaluation of the effect of curcumin-piperine supplement in septic patients

Evaluation of the effect of curcumin-piperine supplement on damage indicators in septic patients admitted to the intensive care unit

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20201220049774N3

Enrollment

Registered

2022-05-14

Start date

2022-05-17

Completion date

Unknown

Last updated

2022-05-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

sepsis. Other sepsis

Interventions

Intervention 1: Intervention group: 33 patients will receive curcumin-piperine supplement after diagnosis of sepsis at a dose of 5.500 mg twice daily for 7 days with antibiotic regimen. Intervention 2

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Age between 18 and 80 years Having sepsis and being admitted to the intensive care unit Signing an informed consent form

Exclusion criteria

Exclusion criteria: Pregnancy and lactation History of allergy to turmeric and curcumin products Age under 18 years HIV patients Member transplant history Rheumatic or autoimmune disease Patients treated with immunosuppressive drugs Patients treated with corticosteroids Radiotherapy Solid or malignant tumor Concomitant use of any supplement with antioxidant or anti-inflammatory effect or immune system regulator Patients without oral / nasal gastrointestinal tract White blood cell count less than 1000 / microliter

Design outcomes

Primary

Measure	Time frame
Serum Lactate. Timepoint: At the beginning of the study and after receiving the last dose of curcumin-piperine. Method of measurement: Laboratory tests.;C-reactive protein (CRP). Timepoint: At the beginning of the study and after receiving the last dose of curcumin-piperine. Method of measurement: Laboratory tests.;SOFA score(Sequential organ failure assessment). Timepoint: At the beginning of the study and after receiving the last dose of curcumin-piperine. Method of measurement: Laboratory tests.	—

Measure

Time frame

Serum Lactate. Timepoint: At the beginning of the study and after receiving the last dose of curcumin-piperine. Method of measurement: Laboratory tests.;C-reactive protein (CRP). Timepoint: At the beginning of the study and after receiving the last dose of curcumin-piperine. Method of measurement: Laboratory tests.;SOFA score(Sequential organ failure assessment). Timepoint: At the beginning of the study and after receiving the last dose of curcumin-piperine. Method of measurement: Laboratory tests.

—

Secondary

Measure	Time frame
Serum creatinine. Timepoint: At the beginning of the study and after receiving the last dose of curcumin-piperine. Method of measurement: Laboratory tests.;WBC count. Timepoint: At the beginning of the study and after receiving the last dose of curcumin-piperine. Method of measurement: Laboratory tests.;Platelet count. Timepoint: At the beginning of the study and after receiving the last dose of curcumin-piperine. Method of measurement: Laboratory tests.;Neutrophil to lymphocyte ratio. Timepoint: At the beginning of the study and after receiving the last dose of curcumin-piperine. Method of measurement: Laboratory tests.;Lymphocyte to monocyte ratio. Timepoint: At the beginning of the study and after receiving the last dose of curcumin-piperine. Method of measurement: Laboratory tests.;Platelet to lymphocyte ratio. Timepoint: At the beginning of the study and after receiving the last dose of curcumin-piperine. Method of measurement: Laboratory tests.;Total Bilirubin. Timepoint: At the beginning of the study and after receiving the last dose of curcumin-piperine. Method of measurement: Laboratory tests.;Direct Bilirubin. Timepoint: At the beginning of the study and after receiving the last dose of curcumin-piperine. Method of measurement: Laboratory tests.	—

Measure

Time frame

Serum creatinine. Timepoint: At the beginning of the study and after receiving the last dose of curcumin-piperine. Method of measurement: Laboratory tests.;WBC count. Timepoint: At the beginning of the study and after receiving the last dose of curcumin-piperine. Method of measurement: Laboratory tests.;Platelet count. Timepoint: At the beginning of the study and after receiving the last dose of curcumin-piperine. Method of measurement: Laboratory tests.;Neutrophil to lymphocyte ratio. Timepoint: At the beginning of the study and after receiving the last dose of curcumin-piperine. Method of measurement: Laboratory tests.;Lymphocyte to monocyte ratio. Timepoint: At the beginning of the study and after receiving the last dose of curcumin-piperine. Method of measurement: Laboratory tests.;Platelet to lymphocyte ratio. Timepoint: At the beginning of the study and after receiving the last dose of curcumin-piperine. Method of measurement: Laboratory tests.;Total Bilirubin. Timepoint: At the beginning of the study and after receiving the last dose of curcumin-piperine. Method of measurement: Laboratory tests.;Direct Bilirubin. Timepoint: At the beginning of the study and after receiving the last dose of curcumin-piperine. Method of measurement: Laboratory tests.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHesamoddin Hosseinjani

Mashhad University of Medical Sciences

hosseinjanih@mums.ac.ir+98 51 3180 1586

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026